Better Choice Company Agrees in Principle to Licensing Agreement in Asia for its Halo Elevate® Brand
Better Choice will receive a 5.5% royalty on all sales of the Halo Elevate Brand in this regionTAMPA, Fla., Feb....
Day: February 20, 2025
Orchestra BioMed to Present at Upcoming Investor Conferences
NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),...
Tectonic Therapeutic to Participate in March Investor Conferences
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused...
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
TUS+VEN+AZA triplet achieves complete responses (CRs) in difficult-to-treat TP53-mutated/CK AML and FLT3-wildtype AML patients, including a measurable residual disease (MRD)...
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net...
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA...
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11%...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences
BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering...
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025
GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it...
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
- Chemical process enhances room temperature stability - - Provisional patent applications filed - PURCHASE, N.Y., Feb. 20, 2025 (GLOBE...
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and...
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company)...
The Joint Corp. to Host Conference Call on Thursday, March 13th to Discuss Fourth Quarter and Year-end 2024 Results
SCOTTSDALE, Ariz., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) a national operator, manager, and franchisor of chiropractic...
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors
Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms...
Promino Nutritional Sciences Inc. Achieves E-Commerce Milestones for Rejuvenate Muscle(TM) Activator on Amazon.com
Burlington, Ontario--(Newsfile Corp. - February 20, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC Pink: MUSLF) (FSE: 93X) (the...
RETRANSMISSION: Hemostemix Licenses CytoImmune’s BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...